Payment overview · 2025
General Payments
$474.14
28 reported records · 9 companies
Healthcare provider profile · identity verified
Chandra Kumar Ponniah, MBBS
Allopathic & Osteopathic Physicians|Family Medicine · NORFOLK, NE · NPI 1881858405
Verified facts
What the public records show
CMS Open Payments records show Chandra Kumar Ponniah, MBBS received $474.14 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.76 | 31.8% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $89.71 | 18.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.15 | 16.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.19 | 10.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.93 | 7.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.38 | 4.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.84 | 4.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.45 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.73 | 2.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.14 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $89.71 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.47 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.82 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.19 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.19 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.31 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.43 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.73 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 612 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 78 |
| Losartan Potassium | Losartan Potassium | 286 | 64 |
| Gabapentin | Gabapentin | 244 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 58 |
| Metformin Hcl | Metformin Hcl | 223 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 58 |
| Eliquis | Apixaban | 198 | 29 |
| Omeprazole | Omeprazole | 173 | 37 |
| Lisinopril | Lisinopril | 160 | 36 |
| Montelukast Sodium | Montelukast Sodium | 143 | 27 |
| Ozempic | Semaglutide | 143 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 31 |
| Carvedilol | Carvedilol | 133 | 22 |
| Sertraline Hcl | Sertraline Hcl | 124 | 27 |
| Potassium Chloride | Potassium Chloride | 121 | 32 |
| Furosemide | Furosemide | 119 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 19 |
| Allopurinol | Allopurinol | 96 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 20 |
| Simvastatin | Simvastatin | 86 | 15 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 15 |
| Jardiance | Empagliflozin | 81 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 19 |
| Metformin Hcl Er | Metformin Hcl | 68 | 19 |
| Donepezil Hcl | Donepezil Hcl | 67 | 12 |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 13 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 16 |
| Trazodone Hcl | Trazodone Hcl | 57 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Celecoxib | Celecoxib | 39 | 11 |
| Linzess | Linaclotide | 39 | suppressed |
| Clozapine | Clozapine | 38 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 26 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.14 · 28 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, Flucelvax, Kerendia, Ozempic, QULIPTA, REXULTI, Rybelsus, TZIELD, UBRELVY, VOQUEZNA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error